Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO …
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20–30% of breast
cancer tumors. In the current investigation, we exploited such a feature and utilized an anti-
HER2 affibody (Z HER2: 477) in combination with a pegylated liposomal doxorubicin (PLD)
for concurrent passive and active targeting of HER2 overexpressing TUBO tumor, using
BALB/c mice. It was determined that the affibody coupled liposomes (affisomes) was
capable of increasing doxorubicin (Dox) delivery to HER2+ cells (SK-BR-3 and TUBO cells) …
cancer tumors. In the current investigation, we exploited such a feature and utilized an anti-
HER2 affibody (Z HER2: 477) in combination with a pegylated liposomal doxorubicin (PLD)
for concurrent passive and active targeting of HER2 overexpressing TUBO tumor, using
BALB/c mice. It was determined that the affibody coupled liposomes (affisomes) was
capable of increasing doxorubicin (Dox) delivery to HER2+ cells (SK-BR-3 and TUBO cells) …
[PDF][PDF] Targeting, bio distributive and tumor growth inhibiting
JASMR Manouchehr - Drugs, 2016 - academia.edu
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20-30% of breast
cancer tumors. In the current investigation, we exploited such a feature and utilized an anti-
HER2 affibody (ZHER2: 477) in combination with a pegylated liposomal doxorubicin (PLD)
for concurrent passive and active targeting of HER2 overexpressing TUBO tumor, using
BALB/c mice. It was determined that the affibody coupled liposomes (affisomes) was
capable of increasing doxorubicin (Dox) delivery to HER2+ cells (SK-BR-3 and TUBO cells) …
cancer tumors. In the current investigation, we exploited such a feature and utilized an anti-
HER2 affibody (ZHER2: 477) in combination with a pegylated liposomal doxorubicin (PLD)
for concurrent passive and active targeting of HER2 overexpressing TUBO tumor, using
BALB/c mice. It was determined that the affibody coupled liposomes (affisomes) was
capable of increasing doxorubicin (Dox) delivery to HER2+ cells (SK-BR-3 and TUBO cells) …
以上显示的是最相近的搜索结果。 查看全部搜索结果